Breaking Finance News

Incyte (NASDAQ:INCY) has been upgraded from Market Perform to Outperform in a statement by Raymond James earlier today.

Raymond James has upgraded Incyte (NASDAQ:INCY) from Market Perform to Outperform in a statement released on 09/29/2016.

Boasting a price of $93.20, Incyte (NASDAQ:INCY) traded 2.17% higher on the day. With the last stock price close up 18.16% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Incyte has recorded a 50-day average of $82.94 and a two hundred day average of $79.80. Volume of trade was up over the average, with 1,707,564 shares of INCY changing hands over the typical 1,190,990

Recent Performance Chart


Incyte has PE ratio of 256.22 with a one year low of $55.00 and a one year high of $128.69 and has a market capitalization of $0.

A total of 14 brokerages have issued a ratings update on Incyte. Seven brokerages rating the company a strong buy, eight brokerages rating the company a buy, one brokerage rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $91.36.

General Company Details For Incyte (NASDAQ:INCY)

Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK). The Company's pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company has discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the compound in its JAK program, which is an oral JAK1 and JAK2 inhibitor. JAKAFI orphan drug is indicated for Myelofibrosis (MF), Polycythemia Vera (PV) and essential thrombocythemia. The Company's second oral JAK1 and JAK2 inhibitor is baricitinib.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.